Scarica l'app Stockscreener
5.87
3.29%
-0.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Savara Inc Borsa (SVRA) Ultime notizie
FDA Extends Review Period for Savara's Molgramostim BLA in Autoimmune PAP - National Today
SVRA stock slips post-market after FDA delays decision on pulmonary therapy - MSN
FDA extends review of Savara’s molgramostim application - Investing.com
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy - Stocktwits
Savara to present molgramostim data at ATS conference in May - Investing.com
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference - National Today
Savara reports 2025 results, advances MOLBREEVI toward approval - MSN
Savara to present molgramostim data at ATS conference in May By Investing.com - Investing.com Australia
Savara Inc. (NASDAQ: SVRA) proxy: MOLBREEVI FDA date, equity and vote items - Stock Titan
Aug PreEarnings: Why is Savara Inc stock going downInsider Buying & Daily Stock Momentum Reports - baoquankhu1.vn
Savara advances MOLBREEVI reviews in US., Europe, UK - MSN
Savara Advances MOLBREEVI Reviews in U.S., Europe, U.K. - MyChesCo
Street Watch: Can Savara Inc withstand a market correctionShare Buyback & Growth Oriented Trading Recommendations - baoquankhu1.vn
Savara (SVRA) Is Up 6.5% After Multi-Region Accelerated Reviews Granted for MOLBREEVI Therapy - simplywall.st
Savara (SVRA) Advances with Regulatory Reviews for Molbreevi - GuruFocus
Savara announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted the Molbreevi* marketing authorisation application (MAA) for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) - marketscreener.com
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
SVRA Technical Analysis & Stock Price Forecast - Intellectia AI
Savara Inc. (SVRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SVRA Stock Price, Quote & Chart | SAVARA INC (NASDAQ:SVRA) - ChartMill
Why Savara (SVRA) Is Up 5.7% After EMA Validates MOLBREEVI Application And FDA Priority Review - simplywall.st
Guggenheim Keeps Their Buy Rating on Savara (SVRA) - The Globe and Mail
Citizens reiterates Savara stock rating on regulatory progress By Investing.com - Investing.com Australia
Citizens reiterates Savara stock rating on regulatory progress - Investing.com
EMA validates Savara’s MOLBREEVI application for autoimmune PAP By Investing.com - Investing.com South Africa
Savara (SVRA) MAA Submission in Europe Receives Validation - GuruFocus
Jefferies reiterates Savara stock Buy rating on approval confidence By Investing.com - Investing.com India
Jefferies sees Savara stock approval odds at 90% for rare lung drug - Investing.com Canada
Jefferies reiterates Savara stock Buy rating on approval confidence - Investing.com UK
Jefferies sees Savara stock approval odds at 90% for rare lung drug By Investing.com - Investing.com South Africa
Savara : Corporate Presentation - marketscreener.com
Savara Inc announced that its Marketing Authorization Application (MAA) for Molbreevi*, a treatment for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), has been formally validated by the European Medicines Agency (EMA). - Bitget
EMA validates Savara’s MOLBREEVI application for autoimmune PAP - Investing.com
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com
Savara grants inducement equity awards to new employee - MSN
Death Cross: Whats the fair value of Savara Inc stockTrade Risk Report & Low Risk Entry Point Tips - baoquankhu1.vn
High Growth Tech Stocks To Watch In The US March 2026 - Sahm
Savara (SVRA) to Release Earnings on Tuesday - MarketBeat
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):